Displaying drugs 426 - 450 of 537 in total
GTI 2040
GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
Investigational
IMO-2055
Investigational
GTI-2040
GTI-2040 is under investigation in clinical trial NCT00084643 (GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors).
Investigational
TNP-2092
TNP-2092 is under investigation in clinical trial NCT03964493 (TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection).
Investigational
APR-2020
APR-2020 is a CD34+ cells that have been transduced in vitro with a lentiviral vector carrying a codon-optimized sequence for expressing the wild type RPS19 protein
Investigational
LY-2090314
Ly2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.
Investigational
BAL200
Investigational
OAV201
OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter. It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical...
Investigational
ECT204
ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational
Poliglusam
Poliglusam, or chitosan, is a linear polysaccharide consisting of D-glucosamine and N-acetyl-D-glucosamine. Naturally-occuring poliglusam is found in the cell walls of fungi, soil and sediments where it is produced from degradation of chitin induced by certain groups of bacteria that produce the enzymes deacetylase or chitosanase enzymes . In comparison,...
Experimental
VTP-201227
VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. It is being developed by Vitae Pharmaceuticals.
Investigational
AGN-201904
Agn 201904 has been used in trials studying the prevention of Peptic Ulcer.
Investigational
RP-L201
Investigational
PEGylated Recombinant Factor VIII
PEGylated Recombinant Factor VIII is under investigation in clinical trial NCT02585960 (BAX 855 Pk-guided Dosing).
Investigational
Matched Synonyms: … Antihemophilic factor (recombinant), pegylated (20 kda) …
Hydroxydione
Hydroxydione (Viadril) is a neuroactive steroid used as a general anesthetic.
Investigational
Withdrawn
AX200
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
GO-203-2C
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
ER2001
Investigational
LX2006
Investigational
LT2003
Investigational
GSK-2018682
GSK2018682 has been investigated for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Investigational
Heptaethylene glycol
Experimental
ARX201
ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH). ARX201 has improved pharmacological...
Investigational
Displaying drugs 426 - 450 of 537 in total